Astellas Pharma (JP:4503) has released an update.
Astellas Pharma Inc. has reported a ¥5.5 billion charge in the first quarter of fiscal year 2024 due to changes in the fair value of contingent consideration for zolbetuximab, largely attributed to foreign currency exchange rate fluctuations. This financial impact is included in Astellas’ recently announced financial results for the initial three months of FY2024. Astellas is a global pharmaceutical company engaged in the development of new drugs for diseases with high unmet medical needs and innovative healthcare solutions.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
